Ubs Asset Management Americas Inc Biocryst Pharmaceuticals Inc Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 691,969 shares of BCRX stock, worth $4.81 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
691,969
Previous 448,466
54.3%
Holding current value
$4.81 Million
Previous $3.36 Million
84.36%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding BCRX
# of Institutions
316Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$143 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$139 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$59.1 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$58.8 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$39.7 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.29B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...